MINIMAL RESIDUAL DISEASE IN ACUTE CHILDHOOD LEUKEMIA
Ashraf Mahmoud Abdelmonem;
Abstract
The present study was conducted on 33 child diagnosed with acute childhood leukemia at SJCRH in Memphis, Tennessee, and POG multi-institutions trial for acute promyelocytic leukemia in the Unites States. Patients were selected based on the availability of cryopreserved bone marrow aspirate samples.
Twenty were males and 13 were females, with ages . ranged from 2.3 to 17 years.
All enrolled patients had bone marrow aspirate and/or biopsy, cytogenetics, immunophenotyping, and molecular testing for the specific fusion genes at time of diagnosis.
Patients were divided into 3 group based on the diagnostic bone marrow, immunophenotyping, and molecular testing.
MRD monitoring was done using RT-PCR to target the characteristic fusion gene (TELlAML1, PMLI RARA, and AML1 /ETO) found at diagnosis in each group.
The 1'1 group was a cohort of 13 patients with ALL expressing the TELlAML1 fusion transcript. In this group the datashowed that patients with TELlAML1 ALL, had exquisite sensitivity to chemotherapy using 6-drug induction protocol with Vincristine, Prednisone, L-asparaginase, Ara-C, VP16, and Daunorubicin. All 13 patients tested at the end of induction therapy as well as follow up samples for 7 patients were negative for MRD using RT-PCR with a reproducible sensitivity of one malignant cell in 105 normal marrow cells.
Twenty were males and 13 were females, with ages . ranged from 2.3 to 17 years.
All enrolled patients had bone marrow aspirate and/or biopsy, cytogenetics, immunophenotyping, and molecular testing for the specific fusion genes at time of diagnosis.
Patients were divided into 3 group based on the diagnostic bone marrow, immunophenotyping, and molecular testing.
MRD monitoring was done using RT-PCR to target the characteristic fusion gene (TELlAML1, PMLI RARA, and AML1 /ETO) found at diagnosis in each group.
The 1'1 group was a cohort of 13 patients with ALL expressing the TELlAML1 fusion transcript. In this group the datashowed that patients with TELlAML1 ALL, had exquisite sensitivity to chemotherapy using 6-drug induction protocol with Vincristine, Prednisone, L-asparaginase, Ara-C, VP16, and Daunorubicin. All 13 patients tested at the end of induction therapy as well as follow up samples for 7 patients were negative for MRD using RT-PCR with a reproducible sensitivity of one malignant cell in 105 normal marrow cells.
Other data
| Title | MINIMAL RESIDUAL DISEASE IN ACUTE CHILDHOOD LEUKEMIA | Other Titles | البقايا القليلة في مرض سرطان الدم الحاد عند الأطفال | Authors | Ashraf Mahmoud Abdelmonem | Issue Date | 2000 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.